Diabetic Neuropathy - Pipeline Insight, 2026

DelveInsight's, "Diabetic Neuropathy - Pipeline Insight, 2026" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Diabetic Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Diabetic Neuropathy: Understanding

Diabetic Neuropathy: Overview

Diabetic neuropathy is a type of nerve damage that can happen with diabetes. Blood sugar, also called glucose, becomes high because of diabetes. Over time, high blood sugar can injure nerves throughout the body. Diabetic neuropathy most often damages nerves in the legs and feet. Diabetic neuropathy is among the most prevalent chronic complications of types 1 and 2 diabetes mellitus (T1DM and T2DM), significantly compromising patients' quality of life and contributing to elevated morbidity and mortality rates.

Depending on the affected nerves, diabetic neuropathy symptoms may include pain and numbness in the legs, feet and hands. It also can cause problems with the digestive system, urinary tract, blood vessels and heart. Some people have mild symptoms. But for others, diabetic neuropathy can be painful and disabling.

The pathogenesis of diabetic neuropathy is multifactorial and remains poorly understood. Hyperglycemia, dyslipidemia, and insulin resistance activate various metabolic pathways, resulting in oxidative stress, mitochondrial dysfunction, inflammation, and microvascular damage, culminating in neuronal injury, Schwann cell damage, and myelin sheath degeneration. Additionally, impaired neurotrophic support and autoimmune mechanisms may further exacerbate neuronal degeneration. Despite extensive research, effective treatments capable of halting or reversing DN's progression remain elusive.

The exact cause of each type of neuropathy is unknown. Researchers think that over time, uncontrolled high blood sugar damages nerves and interferes with their ability to send signals. This process may lead to diabetic neuropathy. High blood sugar also weakens the walls of the small blood vessels called capillaries that supply the nerves with oxygen and nutrients.

Diabetic neuropathy is a common complication of diabetes mellitus characterized by progressive nerve damage due to chronic hyperglycemia, oxidative stress, and microvascular injury. Diagnosis is primarily clinical, beginning with a detailed history of symptoms such as numbness, tingling, burning pain, or loss of sensation, especially in a "stocking-glove" distribution. A thorough neurological examination assessing vibration sense, temperature, pinprick sensation, and reflexes is essential, often supported by simple bedside tools like a monofilament test for early detection of sensory loss. In more complex or uncertain cases, confirmatory investigations such as nerve conduction studies and quantitative sensory testing help evaluate the extent and type of nerve involvement. Early diagnosis is critical, as many patients may remain asymptomatic until significant nerve damage has occurred.

Management focuses on both disease modification and symptomatic relief. Tight glycemic control remains the cornerstone, as it slows progression and reduces further nerve injury. Addressing associated risk factors such as hypertension, dyslipidemia, and obesity also plays a crucial role in limiting disease progression. For symptomatic treatment, medications like anticonvulsants, antidepressants, and topical agents are commonly used to manage neuropathic pain, while opioids are generally avoided due to safety concerns.

"Diabetic Neuropathy - Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Neuropathy pipeline landscape is provided which includes the disease overview and Diabetic Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Neuropathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Neuropathy.

Diabetic Neuropathy Emerging Drugs Chapters

This segment of the Diabetic Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Neuropathy Emerging Drugs

• Suzetrigine: Vertex Pharmaceuticals Incorporated

Suzetrigine is a first-in-class, oral, non-opioid, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that is selectively expressed in peripheral pain-sensing neurons (nociceptors), where its role is to transmit pain signals (action potentials). Because suzetrigine blocks pain signals only found in the periphery, not in the brain, suzetrigine provides effective relief of pain without the limitations of currently available therapies, including the addictive potential of opioids. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Diabetic Neuropathy.

• LX-9211: Lexicon Pharmaceuticals

LX9211 (Pilavapadin) is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target for neuropathic pain which inhibits reuptake and recycling of neurotransmitters involved in pain signaling without affecting opiate pathways. Lexicon identified AAK1 in its target discovery efforts as a promising approach for the treatment of neuropathic pain. Preclinical studies of pilavapadin demonstrated central nervous system penetration and reduction in pain behavior in models of neuropathic pain without affecting opiate pathways. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Diabetic Neuropathy.

• TRV045: Trevena

Trevena is currently developing a novel, selective sphingosine-1-phosphate subtype 1 receptor (S1P1R) modulator, TRV045, as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health, Trevena is also exploring TRV045 as a potential treatment for epilepsy. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Diabetic Neuropathy.

Diabetic Neuropathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Diabetic Neuropathy
• There are approx. 18+ key companies which are developing the therapies for Diabetic Neuropathy. The companies which have their Diabetic Neuropathy drug candidates in the most advanced stage, i.e. Phase III include, Vertex Pharmaceuticals Incorporated.
• Phases

DelveInsight's report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Diabetic Neuropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Neuropathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Neuropathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Neuropathy drugs.

Diabetic Neuropathy Report Insights

• Diabetic Neuropathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Neuropathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Neuropathy drugs?
• How many Diabetic Neuropathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Neuropathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Neuropathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Neuropathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Vertex Pharmaceuticals Incorporated
• Lexicon Pharmaceuticals
• Trevena
• Novo Nordisk A/S
• Zhejiang Anglikang Pharmaceutical Co., Ltd.
• JMackem Co., Ltd
• Eli Lilly and Company
• Centrexion Therapeutics
• WinSanTor, Inc
• Glenmark Pharmaceuticals Ltd

Key Products

• Suzetrigine
• LX-9211
• TRV045
• CagriSema
• BM2216
• AJH-2947
• LY3556050
• CNTX-6016
• WST-057
• GRC 17536